EUVIMEDEUVIMED entdecken
CrossrefInfokarte

In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs

Angela R. Corrigan, Shin Foong Ngiow, Maura Statzu, Amie Albertus, M. Betina Pampena, Jayme M. L. Nordin, Stephen D. Carro, Justin Harper, Rachelle L. Stammen, Jennifer Wood, Houping Ni, Justin Su, Marziyeh Hajialyani, Vladimir V. Shuvaev, Victor Alcalde, Mohammed-Alkhatim A. Ali, Jacob T. Hamilton, Rajesvaran Ramalingam, Vincent H. Wu, Mirko Paiardini, Drew Weissman, E. John Wherry, Edward F. Kreider, Michael R. Betts

Science Immunology · 2026-05-29 · 11 (119)

DOI: 10.1126/sciimmunol.aec3436 ↗
AbstractBibliografische Angaben

Abstract

Selective in vivo reprogramming of cytotoxic effector CD8 T (T eff ) cells holds tremendous promise as a therapeutic tool but has not yet been accomplished. Here, we demonstrate that fractalkine-conjugated mRNA lipid nanoparticles (mRNA-LNPs) can specifically target and deliver mRNA to CX3CR1 + T eff cells in vitro and in vivo. In mice, fractalkine-conjugated mRNA-LNPs targeted up to 95% of blood and splenic T eff cells. In addition, delivery of IL-2–encoding mRNA and human CD62L-encoding mRNA to mouse T eff cells enabled robust exogenous IL-2 secretion and CD62L expression. In rhesus macaques, fractalkine-conjugated mRNA-LNPs targeted up to ~100% of peripheral blood T eff cells, and delivery of human CD62L-encoding mRNA enabled cell-surface human CD62L expression on peripheral blood T eff cells and detection of human CD62L + T eff cells in lymphoid tissue. Collectively, these data demonstrate the potential of natural receptor ligand-based targeting of mRNA-LNPs for rapid, efficient, and transient in vivo modification of T eff cells.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →